Acer Therapeutics — Opexa Therapeutics — IPO Roadshow (July 2013)
39 slides from Acer Therapeutics's IPO roadshow presentation, Jul 22, 2013
Slide 1: Opexa Therapeutics Free Writing Prospectus
Issuer2013 Precision Opexa NASDAQ: July Free Therapeutics, Immunotherapy The Writing OPXA Woodlands, Prospectus Inc. TM TX Filed Pursuant to Rule 433 Registration No. 333-189395 July 22, 2013
Slide 2: Forward-Looking Statements
Forward-Looking This Exchange “estimates,” cautioned Such statements. market financed development success exercise or indication; property and These change 22013 royalties other investor forward-looking and forward-looking conditions; in of its rights; pharmaceutical as risks events, Act that our ou
Slide 3: Free Writing Prospectus Notice
Freeoffering. This We you the website. 3Seventh have should Writing presentation Avenue, Alternatively, filed read You Prospectus a registration the 18th may highlights preliminary Floor, get weStatement these orstatement basic New Aegis documents prospectus York, information Capital (including NYfo
Slide 4: Offering Summary
Offering Exchange/Ticker Issuer Use Over-allotment Sole Opexa NASDAQ Approximately Clinical 4Aegis of Book—Runner Capital Therapeutics, Proceeds Development Summary Size / OPXA Corp. $15 Million Inc. of Tcelna (100%andPrimary) conduct of ongoing Phase IIb Abili-T study, operating expenses, general c
Slide 5: Investment Thesis
Investment T-cell Esteemed Precision Targeting Option Replacement Attractive 5Goal-oriented platform Agreement Immunotherapy an Scientific potential Thesis unmet value management company with of medical risk-reward Advisory company Merck with potentially team need Board Fast Serono, profile isfocuse
Slide 6: Experienced Management Team and Board
Experienced 19+ Co-founder Karthik 10+ MBA, Don 25+ Former Donna 30 Designed Kenny 24 Formerly, Board Gail Michael Scott Executive David Interim Neil 6CEO, years years Warma, J. K. Healey, B. Amplimmune BayBio, Opexa of E. MS Maderis Rill, Frazier, Warma CEO, Senior Director Radhakrishnan, Seaman S.
Slide 7: SPMS Scientific Advisory Board
SPMSS. Dawn Former Hans-Peter Chair President Mark Multiple ACTRIMS Clyde Doug James Edward Director 7Advisory Arnold, of McGuire, Markowitz, McGill Scientific Vice Fox, Freedman, Neurology of Sclerosis ECTRIMS, Council Committee, the MS Multiple Hartung, committee President M.D., M.D. Professor Mul
Slide 8: Pipeline
Pipeline Stage Indication T-CELL Multiple Secondary Relapsing STEM 8*Type Rights 1ofCELL Diabetes and Development PLATFORM granted Sclerosis Remitting Evaluation Progressive Potential PLATFORM to(Tcelna)* Merck MS* Preclinical Areas MS*Phase Serono of Phase Investigation III Phase under IIb notongoi
Slide 9: SPMS Patient Population and Market Opportunity
Patients SPMS Over Approximately Tcelna Potential No 9Upon SPMS 450,000 successful patients ininitially is SPMS being Secondary treatment patients experience pursued 30-45% market experience clinical approved Progressive inin for of development, North the worsening MS this a relapsing-remitting Nort
Slide 10: Preventing Myelin Destruction: Addressing the Root Cause
Preventing Myelin Activation Result T their Opexa’s Tcelna Adapted IMMUNOLOGY cells entry Destruction Addressing programs play Reactive Strategy byinto of Demyelination permission a microglial vital the T-cells the 3,role the central of483-492 immune the Root in from (MRTC) cells myelin our nervous
Slide 11: Mechanism of Action: Tcelna Reduction of MRTC
Mechanism Reduction Tcelna Week C -10% 0% MRT in eduction -60% --50% R -100% -90% Each Results 11 80% -20% -40% dose -30% 0Demonstrated Dose from Week -70% consisting inof 1Tcelna Myelin 5Action Dose Weekdose 2Reactive of a13 Dose Reduction 30-45 Week ranging 3 Dose T-Cells x21 106 studies: in Week
Slide 12: Tcelna Treatment and Manufacturing Process
Single Annual 14 -Red —Blood Epitope Cryopreservation Irradiation dose 12 days as Cross Cycle required course 35 Profiling Group of days Manufacturing each ofAlliance 1injections/year treatment Manufacturing Expansion day subcutaneous (5Process: ofdoses) antigen and from QCspecific Dispensation one
Slide 13: Merck Serono Option Agreement
Merck February Up Option $35 $30 RRMS One Royalties Opexa Development Certain Co-development Rights 13 to million time $220 maintains Serono to exercise development manufacturing 2013 all commercial ranging million FDA for other and Agreement option EU $25 funding key filing, commercialization from
Slide 14: Tcelna Broad Development Program
Tcelna Broad Dates RRMS, (months) Baylor SPMS 2006 escalation Open retreatment TERMS At extension post OLTERMS Phase *Abili-T 14 least TERMS 16 label Duration ICompletion I/II IIb Spectrum (26) Development 1998 dose 1st PPMS, one Expected 122008 15 RRMS SPMS 2007 Half 16 arm dose 114 from RRMS —RRMS
Slide 15: TERMS Completed Phase IIb Clinical Trial
TERMS A Completed mITT 37% ARR Superior Two 0.3 0.35 0.4 nt/year 0.2 0.25 apses/patie 0.214 0nRel 0.05 15 =94 Completed Tcelna 0.339 01. End-of-Phase reduction 0.214 n=48 population 37% Study safety 0.15 Phase vs.Phase in 0.339 and Placebo ARR (n=142) IIb IIpromising IIb meetings clinical vs. Clinic
Slide 16: TERMS Sub-population Analysis
TERMS Sub-population Percent 0at -0.05 -0.04 -0.1 -0.15 55% change me volu -0.25 -0.35 Baseline 88% Brain These 16 n=18 Week %) 2.35 (Reduction Tcelna 2.4 2.2 2.1 Atrophy -0.3 -0.2 Data 88% n=32 (Mean) Brain 52 Study—Prospective Week 2.4 0.5 2.2 0 -0.32 Sc at Support Placebo 2.3 2.39 (p=0.045) 2.45
Slide 17: TERMS Subgroup Analysis
TERMS 1.4 1.2 (ARR) te Ra Relapse Tcelna dp=0.046 0.4 Annualize 0.21 00.2 mITT Annualized MS. 17p=0.060 n=53 10.8 73% p=0.009 0.48 In 0.18 ARR>1 64% 1.18 this n=28 0.6 0.5 Reduction Study—Subgroup 0.31 subpopulation, relapse 56% Reduction n=45 ARR>1 Reduction n=25 rate inn=16 DMT treatment Analysis
Slide 18: Secondary Progressive MS Overview: Promising Efficacy
Secondary Overview 36 35 26 Promising Disease 10 Well-tolerated No 18 SPMS of patients worsening Serious these stabilization patients of efficacy Progressive treated in patients Adverse Phase Opexa in with key treated atobserved I/II awere Events as sponsored Baylor; Quality favorable Patients MS: m
Slide 19: Tcelna Stabilizes Disease Progression in SPMS
80% wing n100% Sho tients 60% Stable Pa of ent Perc Tcelna 0% (n=35) *A improvement 1980% 40% St small Disease 80% 20% of Stabilization 40% abilizatio Stabilizes Open Progression subjects percentage 20% Label (i.e. Progressed treated Disease decrease vs. Historical ofHistorical patients with ininSPM
Slide 20: Tcelna Reduces Annualized Relapse Rate in SPMS
Tcelna 060. patients (ARR) eIn 0elapse R nualized Baseline 0.00 An One 20 .20 at21.8 0.40 relapse Tcelna 0.30 Reduces 0.50 years (n=10) 0.10 patient 12 patient treated Months observed of Annualized cumulative follow experienced SPMS 24inup, Months 21 only years Relapse 11of relapse cumulative Rate (
Slide 21: Tcelna Stabilizes Quality of Life Scale Impact
Tcelna Scale Impa ct (n=10) 2.0% lerosis Sc Multiple n0.0% iC age Negative Percent Following condition 21hange -20%. 0.9% -51%. Tcelna 2.1% 4.0% 1.2% Stabilizes (n=7) -6.0% -4.0% Physical 12 percent and two Month treated improvement improvement years Quality change 18-24 Tcelna of treatment, indicat
Slide 22: Abili-T Phase IIb Trial Design
Abili-T Double-blind, Inclusion 53 Immune Fast 180 SPMS 230 22 patients sites Patients Track population :in Phase annual Monitoring Landmark criteria: USA designation enrolled expected IIb 1:1 courses andclinical Secondary randomized, trial at Canada program to June granted of in be trial personaliz
Slide 23: Abili-T Efficacy Endpoints
Efficacy Primary Whole-brain Secondary Sustained Time T2 Annualized Exploratory Quality Gd-enhancing Change Changes 23 lesions to of in sustained Endpoint Assessments inprogression life EDSS MSFC Symbol MTR progressing Endpoints T-regulatory Relapse Endpoints atrophy lesion assessment inAssessment p
Slide 24: Immune Monitoring Program
Immune Trial 2012 Immuno (CD4 Whole Absolute cells, and TH17 TH2 Goal impact IL-2 response, Precision IL-17E, Tcelna IL-23 depleting of ?H 24LA-G, T-cells Monocytes IL-4 TNF?) initiation is 2013 B-cells, and IL-27 Tr1 differentiates blood on to IL-17F Monitoring ICOS) vigilance frequency aImmunother
Slide 25: Pro Forma Principal Financials
ProPrincipal Financials Cash Convertible Shares Warrants Stock (1) 25 forma and Options Outstanding (MM) Cash asDebt outstanding of(MM) Equivalents June (2) (MM) ~3.1 (MM) 30, (3) (1) 2013 ~1.1 on~8.1 (MM) $convertible 3.2 $ 5.0 debt (2) Weighted average exercise price =$4.12 (3) Weighted average ex
Slide 26: Goals and Present Milestones
Goals and Present Activate Advance Evaluate 26 Immune Canadian and and potential Milestones initiate present complete Monitoring of sites all T-cell interim enrollment Abili-T andplatform initiate base immune clinical line inenrollment in Phase monitoring data additional sitesatIIb in ACTRIMS Abili-
Slide 27: Investment Highlights
Investment Lead Currently Limited Potential Tcelna Option Opexa’s In FDA 27 previous has product, positioned and treatment in-house granted SPMS conducting Highlights license MSTcelna®, clinical market Opexa cGMP as options agreement potential a Phase in studies, aFast manufacturing T-cell currently
Slide 28: Appendix
28 APPENDIX
Slide 29: Tcelna Clinical Progress Highlights
Tcelna® Clinical ?Progress Safety Dose Commercial Secondary Abili-T Fast Relapsing Formal FDA 29 Overtrack feedback and demonstrated 850 End Phase studies Highlights made regimen designation Remitting Progressive Tcelna of opportunities IIobtained Phase on conducted SPMS manufacturing for preparatio
Slide 30: Tcelna Personalization Manufacturing Process
Tcelna Personalization The Screen 109 Interferon ImmPathTM Procure Manufacturing Process 30 overlapping Epitope Manufacturing: peripheral generates unit gamma Profiling of Process performed blood followed peptides blood aresponse year from Assay for of by encompassing under which Tcelna to Myelin-Re
Slide 31: Tcelna Proprietary Manufacturing
Tcelna Proprietary Year Conduct Re-assess Develop 1 Manufacturing: newly analysis epitope Assay personalized of profile Enables 109Precision peptides annually Annual formulation Medicine from to Personalized identify allannually three epitope key Treatments based myelin shifton proteins evolved (MBP
Slide 32: TERMS Safety Summary
TERMS Safety Deaths Serious Most 32 common Summary No Adverse Study: deaths adverse Safety Events occurred Overview events (SAEs)Mild No to treatment-related moderate injection SAEssite reaction
Slide 33: Abili-T Efficacy Assessments Schedule
Abili-T Screen P T1 EDSS Neuro SDMT MSFC MSQLI Efficacy MRI EDSS: NEURO: SDMT: MSFC: MSQLI: MRI: 33IM1 T2Magnetic T3 EDSS IM2 Neuro MSFC Screen Expanded SDMT Annual MS Symbol MRI Assessments MS Neurological T4IM3 Functional Quality T5 EDSS Neuro MSQLI MSFC Baseline SDMT Treatment Resonance Digit IM4
Slide 34: Mechanism of Action
Mechanism Attenuated, MRTC Therapeutic Down-regulation Potential Phase lower 34 relapse I/II expanded tostudies induce patient-specific of scrates Action dosing of ex conducted and up-regulation similar vivo (30-45 stabilization in endogenous (autologous) response with x 106 of Tcelna cells) regulat
Slide 35: Mechanism of Action: Tcelna Observations
Mechanism Tcelna Observations Increase p=0.971 Pre-Tcelna Post Clinical All Showed 35 three -Tcelna increases findings astabilization (i.e. in patients 57%-67% (non-detectable) Tr1 ofnoAction cells statistical Tr1 in (who Tcelna from to reduction cells ofahad disease level non-detectable in differen
Slide 36: Mechanism: The SPMS Immunopathology
Mechanism The SPMS -Immunological 36 A Microglia Mechanisms In SPMS Levels therapeutic SPMS, Immunopathology isis of associated characterized the it activation ofisresponsible Action anti-inflammatory that defects believed has with suggests associated of the by that compartmentalized inflammatory SP
Slide 37: Baseline SPMS Subjects Have Reduced TR1 Cells
Baseline SPMS 54CD4+CD18brightCD49b+ sc15 T CD4+ ofells 0% 010 Healthy Donors ** ACTRIMS 37 of % 1TR1: T subjects cell Abili-T *(p=0.02) **CD4+ CD4+ 3 2013have patients TR1: a reduced 2 Healthy Patients SPMS** (p=0.01) Donors Poster: versus CD4+CD45RA-LAG3+CD49b+ SPMS frequency Patients ProfilingHea
Slide 38: SPMS Frequency of Foxp3+ nTregs
SPMS Frequency where Foxp3+ CD4+CD127-CD25bright 1.0 cells T + CD4 % *00. I0.6 of* 0.8 Healthy Donors ACTRIMS 38 0.4 0.2 25000 15000 reduction subjects nTregs: 020000 MF 5000 of 10000 nTregs Patients SPMS (p=0.06) 2013 have Foxp3+ in Tregsmay reduced may Healthy Donors (p=0.56) Poster: nTregs: be Fo
Slide 39: SPMS Patients Have Fewer Anti-inflammatory Monocytes
SPMS PD-L1+ 6CD14+CD16-ICOS+PD-L1+ 39 ytes Monoc 1.5 onv 1.0 C of % Healthy Donors ** ACTRIMS C 0of patients (p=0.004) 2% 0.5 **onv 0.02.0 Monocytes: 4ytes Patients SPMS Monoc 2013have fewer HLA-G+ (p=0.164) Healthy Donors Poster: Anti-inflammatory SPMS CD14+CD16-ICOS+HLA-G+ Monocytes: Patients Prof